LA
CMIIU

Linden Advisors’s CM Life Sciences II Inc. Unit CMIIU Stock Holding History

Linden Advisors’s Portfolio CMIIU Stock Details CMIIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-250,000
Closed -$3.2M – 1034
2021
Q1 		$3.2M Buy
+250,000
New +$3.14M 0.02% 389

Other funds holding CMIIU

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
TCIM
TOMS Capital Investment Management New York $3.81B AUM 26.36% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
IM
Islet Management New York $49.1M AUM 17.59% 1-Year Est. Return

Linden Advisors's CMIIU Position: Q2 2021 in Review

Linden Advisors sold out of CM Life Sciences II Inc. Unit (CMIIU) in Q2 2021, closing a stake of 250,000 shares — an estimated $3.2M sold.

Linden Advisors first reported a position in CMIIU in Q1 2021 and held it in 1 quarter. The position peaked at $3.2M in Q1 2021. 38 funds tracked by Wall St. Rank hold CMIIU as of Q2 2021.

  • Linden Advisors reported no remaining CM Life Sciences II Inc. Unit position as of Q2 2021 after selling out during the quarter.
  • Linden Advisors sold 250,000 CM Life Sciences II Inc. Unit shares in Q2 2021, an estimated $3.2M.
  • Linden Advisors first reported a position in CM Life Sciences II Inc. Unit in Q1 2021 and held it in 1 quarter.
  • Linden Advisors's CM Life Sciences II Inc. Unit position peaked at $3.2M in Q1 2021.
  • 38 funds tracked by Wall St. Rank held CM Life Sciences II Inc. Unit as of Q2 2021.

Based on Linden Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.